Autolus Therapeutics (NASDAQ:AUTL) Posts Earnings Results, Beats Expectations By $0.12 EPS

Autolus Therapeutics (NASDAQ:AUTL) announced its earnings results on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12, Zacks reports. The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $2.98 million.

Autolus Therapeutics Price Performance

AUTL opened at $1.68 on Friday. Autolus Therapeutics has a 1-year low of $1.66 and a 1-year high of $6.60. The stock has a market cap of $445.71 million, a P/E ratio of -1.38 and a beta of 2.07. The stock’s 50 day simple moving average is $2.03 and its 200 day simple moving average is $2.93.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, January 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $10.40.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.